[{"Assets_0_Q2_USD":967732000.0,"CommonStockSharesOutstanding_0_Q2_shares":52637375.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-210844000.0,"NetIncomeLoss_1_Q2_USD":-101190000.0,"NetIncomeLoss_2_Q2_USD":-178885000.0,"StockholdersEquity_0_Q2_USD":312350000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":23757000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":42279000.0,"Ticker":"CLVS","CIK":"1466301","name":"CLOVIS ONCOLOGY, INC.","OfficialName":"Clovis Oncology Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"317205570.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180802"}]